December 4, 2015: New Breast Cancer Drug Information

December 4, 2015: New Breast Cancer Drug Information

Breast Cancer Drug Information

• December 4, 2015
• Reading time: 1 minute

The key points from this report, translated and summarized as follows:

On November 20, 2015, GlaxoSmithKline announced that lapatinib (brand name: Tykerb), a PTK inhibitor targeting EGFR and HER2, has been approved by Japan's Ministry of Health, Labour and Welfare. This is a drug suitable for breast cancer patients who are inoperable or have recurrent disease and can be used in combination with aromatase inhibitors such as letrozole.

Source: https://glaxosmithkline.co.jp/press/press/2015_07/P1000927.html

#Breast Cancer

• Clinical Trial Drug

  (Lung Cancer) Topotecan and Topotecan + Berzosertib Show Promising Results in Phase II Trial. (Lung Cancer) HER2 Gene Mutation Non-Small Cell Lung Cancer: Is Enhertu Effective? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Related Cancer Information

• Breast cancer
• Lung cancer